A Phase 4 interventional study of Ferric Carboxymaltose Injection [Ferinject] in Acute Coronary Syndromes (ACS), Iron Deficiencies and Elderly (People Aged 65 or More), sponsored by Fundación para la Investigación del Hospital Clínico de Valencia. Recruiting at 9 sites in Spain. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-03-24.
Sponsored by Fundación para la Investigación del Hospital Clínico de Valencia · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 85 studies in Acute Coronary Syndrome with a site in Spain — 13 open to participants now, 16 under way, 1 of them phase 3. Acute Coronary Syndrome · Spain.
Among the 85 studies in Acute Coronary Syndrome with a site in Spain, this one is the 31st largest by planned enrollment of the 60 interventional ones that give a count, is one of 4 that started in 2026, is one of 12 in phase 4, reaches primary completion later than 11 of the 15 other live ones, and was the 83rd registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.
Browse Acute Coronary Syndrome studies →13 of the 85 studies in Acute Coronary Syndrome with a site in Spain are open now. Recruiting first, the newest first:
Kristian Rivera · Sites in Spain, Mexico
Ages 18+
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz · Sites in Spain, Ireland, Latvia and 2 more countries
Ages 18+
Ceric Sàrl · Sites in Spain
Ages 18+
Abcentra · Sites in Spain, United States, Czechia and 6 more countries
Ages 18+
Spanish Society of Cardiology · Sites in Spain
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
85 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 538 is above the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 588 across the 60 interventional studies, 900 across the 25 observational. Of the 58 that completed or were terminated, 20 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
33 of 85 have an industry lead sponsor. The 10 most frequent:
Fundación para la Investigación del Hospital Clínico de Valencia is the lead sponsor of 73 studies on the registry; 18 are open to participants now.
Fundación para la Investigación del Hospital Clínico de Valencia has 1 study filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Acute Coronary Syndrome with a site in Spain that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07102628Phase 3Novartis PharmaceuticalsEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes | 2027-01-16 |
| NCT06736665Spanish Society of CardiologyOrbital Atherectomy vs Intravascular Lithotripsy for the Treatment of Calcified Coronary Nodules (ORBIT-SHOCK). | 2026-12 |
| NCT06927739AbcentraFocused Orticumab Research for Treating Inflammation in Coronary Arteries | 2027-02-08 |
| NCT07091682Biotronik AGSafety and Clinical Performance of the Freesolve Resorbable Magnesium Scaffold System in the Treatment of Subjects With Long de Novo Lesions | 2027-06 |
| NCT07038265Institut d'Investigació Biomèdica de BellvitgePatient-centered Personalized Cardiac Rehabilitation in Post Acute Coronary Syndrome (BREAK-trial) | 2027-11 |
Add all 5 to your calendar (.ics) → With an account.
Among the 85 studies in Acute Coronary Syndrome with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this phase IV, open-label, randomized clinical trial is to evaluate whether intravenous iron improves quality of life in adults aged 65 years and older with iron deficiency after an acute coronary syndrome (ACS).
The main questions it aims to answer are:
Researchers will compare intravenous ferric carboxymaltose with standard of care.
Participants will:
Acute coronary syndrome (ACS) remains one of the leading causes of morbidity and mortality in adults aged 65 years and older. Iron deficiency is a frequent condition in this population following an ACS event and has been associated with impaired functional capacity, increased frailty, worse quality of life, and poorer clinical outcomes. While intravenous iron supplementation has demonstrated clinical benefits in patients with heart failure, its role in older patients with iron deficiency after ACS has not been systematically evaluated.
This phase IV, multicenter, open-label, randomized clinical trial has been designed to assess the impact of intravenous iron administration on quality of life and clinical outcomes in older patients with iron deficiency following ACS. The study will include patients aged 65 years or older diagnosed with ACS within the previous 15 days and presenting with iron deficiency according to current European Society of Cardiology criteria.
Eligible participants will be randomized in a 1:1 ratio to receive either a single intravenous dose of ferric carboxymaltose, administered according to body weight and baseline hemoglobin levels, or standard of care without intravenous iron supplementation. Randomization will be centralized and stratified by participating center. Given the nature of the intervention, the study will be conducted in an open-label fashion.
Participants will be followed for 12 months after randomization, with study visits scheduled at baseline, 6 months, and 12 months. Throughout follow-up, comprehensive clinical assessments will be performed, including evaluation of quality of life using the EQ-5D-5L questionnaire and assessment of frailty using the FRAIL scale. Clinical events such as heart failure decompensation, recurrent myocardial infarction, stroke, and all-cause mortality will be systematically recorded.
In addition, serial blood samples will be collected to analyze iron metabolism parameters and inflammatory biomarkers. Exploratory analyses will focus on the assessment of biological aging and cardiovascular risk markers, including DNA methylation of the ELOVL2 gene, telomere length, and circulating levels of Klotho and fibroblast growth factor 23 (FGF23). These analyses aim to provide mechanistic insights into the potential effects of iron repletion on biological aging and cardiovascular risk in this vulnerable population.
The overall duration of the study is two years, including a one-year recruitment period and a one-year follow-up period. The trial is sponsored by INCLIVA - Health Research Institute and conducted across multiple centers in Spain. The results of this study are expected to provide robust clinical evidence to support optimized management of iron deficiency in older patients following ACS, with the potential to inform future clinical guidelines and improve patient-centered outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Iron deficiency diagnosed at admission or within 15 days after the index ACS event, defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intravenous iron administered according to protocol and SmPC.
Drug: Ferric Carboxymaltose Injection [Ferinject]
No specific intervention for iron deficiency (standard of care post-acute coronary syndrome)
Intervention Description (Treatment Arm) Single intravenous administration of ferric carboxymaltose (Ferinject®) given at baseline within 15 days after the index acute coronary syndrome. The total iron dose is individually calculated according to body weight and hemoglobin levels, in accordance with the approved Summary of Product Characteristics (maximum 15 mg/kg, not exceeding 2,000 mg). The drug is administered in a monitored hospital setting. No additional iron doses are planned during follow-up. Intervention Description (Control Arm) Standard post-acute coronary syndrome care without specific treatment for iron deficiency. No intravenous or oral iron supplementation is administered per protocol.
Change from baseline in health-related quality of life measured using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L) index score
Change from baseline in health-related quality of life assessed using the EuroQol 5-Dimension 5-Level questionnaire (EQ-5D-5L). The EQ-5D-5L index score ranges from 0 to 1, where 0 represents the worst health state and 1 represents full health. Higher scores indicate better health-related quality of life. Scores will be evaluated at 6 and 12 months and compared with baseline between participants receiving intravenous ferric carboxymaltose and those receiving no iron treatment.
Time frame: Baseline, Month 6 and Month 12.
Change from baseline in frailty status assessed using the Fatigue, Resistance, Ambulation, Illnesses, and Loss of Weight (FRAIL) scale
Change from baseline in frailty status assessed using the Fatigue, Resistance, Ambulation, Illnesses, and Loss of Weight (FRAIL) scale. The FRAIL scale classifies participants as robust, pre-frail, or frail based on questionnaire responses.
Time frame: Baseline, Month 6 and Month 12.
Incidence of heart failure hospitalization
Occurrence of hospitalizations due to decompensated heart failure during follow-up.
Time frame: Up to 12 months
Incidence of recurrent myocardial infarction
Occurrence of non-fatal myocardial infarction during follow-up.
Time frame: Up to 12 months
Incidence of stroke
Occurrence of ischemic or hemorrhagic stroke during follow-up.
Time frame: Up to 12 months
All-cause mortality
Death from any cause during the 12-month follow-up period.
Time frame: Up to 12 months
Change in C-reactive protein levels (inflammatory marker)
Change from baseline in C-reactive protein (CRP) levels. Units: mg/dl
Time frame: Baseline and 12 months follow-up
Change in high-sensitivity C-reactive protein levels (inflammatory marker)
Change from baseline in high-sensitivity C-reactive protein (CRP) levels. Units: mg/L
Time frame: Baseline and 12 months follow-up
Change from baseline in serum ferritin concentration
Change from baseline in serum ferritin concentration measured in blood samples in a predefined subgroup of participants. Units: ng/mL
Time frame: Baseline and 12 months
Change from baseline in transferrin saturation
Change from baseline in transferrin saturation (TSAT) measured in blood samples in a predefined subgroup of participants. Transferrin saturation will be reported as percentage (%).
Time frame: Baseline and 12 months
Change from baseline in soluble transferrin receptor concentration
Change from baseline in soluble transferrin receptor (sTfR) concentration measured in blood samples in a predefined subgroup of participants. Concentrations will be reported in milligrams per liter (mg/L).
Time frame: Baseline and 12 months
Change from baseline in serum hepcidin concentration
Change from baseline in serum hepcidin concentration measured in blood samples in a predefined subgroup of participants. Concentrations will be reported in nanograms per milliliter (ng/mL).
Time frame: Baseline and 12 months
Change from baseline in hypoxia-inducible factor 1 (HIF-1) levels
Change from baseline in hypoxia-inducible factor 1 (HIF-1) levels measured in blood samples in a predefined subgroup of participants. Values will be reported in ng/ul.
Time frame: Baseline and 12 months
Change from baseline in interleukin-1 concentration
Change from baseline in interleukin-1 (IL-1) concentration measured in blood samples in a predefined subgroup of participants. Values will be reported in nanograms per microliter (ng/µL).
Time frame: Baseline and at 12 months follow-up
Change from baseline in interleukin-6 concentration
Change from baseline in interleukin-6 (IL-6) concentration measured in blood samples in a predefined subgroup of participants. Values will be reported in nanograms per microliter (ng/µL).
Time frame: Baseline and at 12 months follow-up
Change from baseline in interleukin-10 concentration
Change from baseline in interleukin-10 (IL-10) concentration measured in blood samples in a predefined subgroup of participants. Values will be reported in nanograms per microliter (ng/µL).
Time frame: Baseline and at 12 months follow-up
Change from baseline in interleukin-18 concentration
Change from baseline in interleukin-18 (IL-18) concentration measured in blood samples in a predefined subgroup of participants. Values will be reported in nanograms per microliter (ng/µL).
Time frame: Baseline and at 12 months follow-up
Change from baseline in tumor necrosis factor alpha concentration
Change from baseline in tumor necrosis factor alpha (TNF-α) concentration measured in blood samples in a predefined subgroup of participants. Values will be reported in nanograms per microliter (ng/µL).
Time frame: Baseline and at 12 months follow-up
Change from baseline in epigenetic age acceleration measured by ELOVL2 DNA methylation
Change from baseline in epigenetic age acceleration assessed using DNA methylation of the ELOVL2 gene in blood samples from a predefined subgroup of participants. Epigenetic age acceleration will be reported in years of biological age.
Time frame: Baseline and at 12 months follow-up
Change from baseline in telomere length
Change from baseline in telomere length measured using the telomere-to-single copy gene (T/S) ratio in blood samples from a predefined subgroup of participants.
Time frame: Baseline and at 12 months follow-up
Association between baseline Klotho concentration and occurrence of major adverse cardiovascular events.
Association between baseline Klotho concentration measured in blood samples and the occurrence of major adverse cardiovascular events (MACE) during follow-up in a predefined subgroup of participants. Klotho concentrations will be reported in nanograms per microliter (ng/µL).
Time frame: Baseline and through Month 12 follow-up.
Association between baseline fibroblast growth factor 23 concentration and occurrence of major adverse cardiovascular events.
Association between baseline fibroblast growth factor 23 (FGF23) concentration measured in blood samples and the occurrence of major adverse cardiovascular events (MACE) during follow-up in a predefined subgroup of participants. Concentrations will be reported in nanograms per microliter (ng/µL).
Time frame: Baseline and through Month 12 follow-up.
Plan to share: Undecided
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Apr 2028, 25 months after the start.
Of 85 non-industry phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 25 months is below that.
Counting every sponsor, half of 92 studies reached it within 42 months; a quarter within 26 and three quarters within 60.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric carboxymaltose
Fundación para la Investigación del Hospital Clínico de Valencia